Glaxo Canada
Executive Summary
Research collaboration with Canadian biotech firm Allelix Biopharmaceuticals will focus on bone disorders, including osteoporosis, bone cancer and bone fractures. Glaxo Canada is providing a minimum of $ 10 mil. over five years. One of the first projects will be the production via genetic engineering of parathyroid hormone, for use in treating osteoporosis. Allelix is also investigating the cytokine interleukin-6 for inflammation under an agreement with Rhone-Poulenc.